• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » AdvanSource Biomaterials demotes itself, posts Q2 sales and earnings reversals

AdvanSource Biomaterials demotes itself, posts Q2 sales and earnings reversals

November 17, 2010 By MassDevice staff

ASB logo

AdvanSource Biomaterials Corp. (NYSE:ASB) is moving its stock out of the New York Stock Exchange effective Nov. 16, rather than be de-listed by the exchange after falling afoul of its equity and profitability requirements.

The Wilmington, Mass.-based advanced polymer maker also posted dismal results for its fiscal 2011 second quarter, notching sales and earnings reversals compared with the same period last year.

The NYSE warned AdvanSource in August that it risked a de-listing because it fell short of its equity and profitability requirements.

At the close of the AdvanSource’s fiscal quarter ending June 30, the company reported stockholders’ equity of $5.8 million, just shy of the NYSE’s $6 million threshold. In addition, the company had net losses and losses from continuing operations in its five most recent fiscal years. In September the company submitted its plan to regain the exchange’s good graces, which apparently fell short. AdvanSource said that, rather than appeal the imminent de-listing, it would shift its stock to the Over-The-Counter Bulletin Board.

As if to add insult to injury, AdvanSource today announced losses of $710,000, or 3 cents per share, on sales of $491,000 during the three months ended Sept. 30, a top-line decline of 5.2 percent compared with the same period last year. The bottom line slid from profits of $191,000 during the second quarter of fiscal 2010, on sales of $518,000.

President and CEO Michael Adams said the company believes its license, royalty and development fee revenues “bottomed” last quarter and that it can build on two new contracts with medical device manufacturers.

AdvanSource reported cash and equivalents of $1.9 million, down 39 percent from $3.1 million as of March 31. ASB shares closed at 17 cents today, down nearly 20 percent.

Filed Under: Business/Financial News, Contract Manufacturing, MassDevice Earnings Roundup, News Well Tagged With: AdvanSource Biomaterials Corp.

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy